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Background: Cardiac sarcoidosis (CS) is a potentially life-threatening condition. At present, there is no consensus
with regard to the optimal non-invasive clinical evaluation and diagnostic procedures of cardiac involvement in
patients with sarcoidosis. The aim of this study in a large homogenous Scandinavian sarcoidosis cohort was
therefore to identify risk factors of cardiac involvement in patients with sarcoidosis, and the value of initial routine
investigation with ECG and cardiac related symptoms in screening for CS.
Methods: In this retrospective study a cohort of 1017 Caucasian patients with sarcoidosis were included. They were
all screened with ECG at disease onset and investigated for CS according to clinical routine.
Results: An abnormal ECG was recorded in 166 (16.3%) of the 1017 patients and CS was later diagnosed in 22
(13.2%) of them, compared to in one (0.1%) of the 851 sarcoidosis patients with a normal ECG (p < 0.0001). The risk
for CS was higher in patients with a pathologic ECG combined with cardiac related symptoms (11/40) (27.5%)
compared to those with pathologic ECG changes without symptoms (11/126) (8.7%) (p < 0.01). Furthermore,
patients with Löfgren’s syndrome had a reduced risk for CS compared to those without (p < 0.05) the syndrome.
Conclusions: This study on an unusually large and homogenous sarcoidosis population demonstrate the
importance of an abnormal ECG and cardiac related symptoms at disease onset as powerful predictors of a later
diagnosis of cardiac sarcoidosis. In contrast, CS is very rare in subjects without symptoms and with a normal ECG.
This knowledge is of importance, and may be used in a clinical algorithm, in identifying patients that should be
followed and investigated extensively for the presence of CS.
Keywords: Cardiac sarcoidosis, Extra-pulmonary involvement, Cardiovascular magnetic resonance, Human leukocyte
antigen, SarcoidosisIntroduction
Sarcoidosis is an inflammatory disease affecting the lungs
and/or intrathoracic lymph nodes in 90% of the cases. It is
characterized by the formation of non-necrotizing granu-
lomas in the affected organs and almost any organ can be
affected leading to a highly variable clinical presentation
[1,2]. In patients with cardiac sarcoidosis (CS) is the inter-
ventricular septum commonly engaged, leading to damage
of the conduction system [3]. Engagement of the heart* Correspondence: pernilla.darlington@ki.se
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distribution, and reproduction in any mediummay therefore manifest itself as benign arrhythmias or give
rise to severe conduction blocks and in worst case life
threatening arrhythmias secondary to infiltration of the
cardiac conduction system or the myocardium [4]. Gluco-
corticoid treatment is usually recommended in patients
with CS to suppress the inflammation and disease pro-
gression [5]. CS is believed to occur in about 5% of all pa-
tients with sarcoidosis, but heart biopsy samples from
deceased patients with a diagnosis of sarcoidosis indicate
that the incidence of cardiac engagement is likely to be
higher [6,7]. Studies of autopsy materials also show that
cardiac involvement is considerably more common in
Japanese patients than in Caucasians, indicating that eth-
nic/genetic factors might be of significant importance [8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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lomas is considered diagnostic for CS, it is highly inva-
sive and difficult to obtain. In addition, a negative biopsy
does not exclude CS. At present, there is no consensus
with regard to the optimal non-invasive clinical evaluation
and diagnostic procedures of patients with suspected car-
diac involvement in sarcoidosis, and thus improvement in
patient evaluation strategies might help in defining the pa-
tients at high risk of cardiac involvement [9].
The overall objective of this study of a large cohort of
well-characterized Scandinavian patients with a primary
diagnosis of sarcoidosis was to investigate the value of
resting electrocardiogram (ECG) and clinical symptoms
in the early identification of CS. In addition, different




In this retrospective study, 1017 consecutively recruited
sarcoidosis patients of Caucasian origin were included
(Table 1). The majority were recruited from a single cen-
ter in Stockholm, Sweden, and were screened with ECG
at disease onset. All patients had initially been referred
for a first diagnostic investigation and activity assessment
of sarcoidosis. Patients with non-resolving disease, i.e.
signs of activity according to the criteria defined by Costa-
bel et al. [10], were followed for several years and investi-
gated for CS upon clinical suspicion of heart engagement
at later timepoints if deemed indicated. All patients fur-
ther investigated for CS were examined in line with the
routine at the out-patient clinic (see below). All patients
had been diagnosed with sarcoidosis through typical clin-
ical and chest radiographic manifestations, findings at
bronchoscopy with bronchoalveolar lavage (BAL) includ-






Gender M/F 107/59* 473/378







*p < 0.05 compared to the ratio of male/female gender among patients with a
normal ECG. ^Age, years at time for diagnosis: values are medians (min – max).
##p < 0.01 compared to the ratio of stage II-IV among patients with a normal
ECG. **p < 0.01 compared to the ratio of LS/non-LS patients with a normal
ECG. ). #p < 0.05 compared to the ratio of alive/diseased with a normal ECG.biopsies, using the criteria outlined by the World Associ-
ation of Sarcoidosis and other Granulomatous disorders
(WASOG) [7]. Patients were defined as ever smokers if
they had previously smoked or were current smokers.
Chest radiographs were evaluated and findings staged by
one of the authors (chest radiologist K. C.). Chest radio-
graphs in patients with sarcoidosis were classified into five
stages: Stage 0 - normal; Stage I - bilateral hilar lymph-
adenopathy; Stage II - bilateral lymphadenopathy with
parenchymal infiltrates; Stage III – parenchymal infil-
trates alone; Stage IV - fibrotic bands and volume reduc-
tion [11]. Patients described as having parenchymal
lung infiltrates included them with stage II-IV. Löfgren’s
syndrome (LS) (n = 386) was defined as bilateral hilar
lymphadenopathy with or without parenchymal infiltra-
tion, fever, erythema nodosum and/or ankle arthritis.
An evaluation of deceased patients was performed in
August 2013. This was possible since patient records do
simultaneously operate with the tax authority system
registrating all citizens. Data was missing for those who
were no longer residents in Sweden.
Patient characteristics for the whole group are de-
scribed in Table 1, divided into patients with a patho-
logic ECG and those with a normal ECG. The frequency
of ECG changes judged as pathological are described in
Table 2. The diagnosis CS was guided by the Japanese
guidelines by Hiraga et al. [12] in the vast majority of
cases. A few subjects did not fulfill all the criteria in the
guidelines but they were regarded having CS after care-
ful cardiological investigation. An additional magnetic
resonance imaging (MRI) had not been performed in all
patients since this has become a routine only recently.
All patients diagnosed with CS were evaluated by one of
the authors (cardiologist A. G.). Characteristics forTable 2 Frequency (%) of different symptoms and
changes regarded as pathologic on ECG in patients with




Pathologic changes Atrioventricular block 9.6
Right bundle branch block 13.9
Incomplete right bundle branch
Block 4.2
Left bundle branch block 2.4
Left anterior fascicular block 13.9
Unspecific bundle branch block 1.2
Premature ventricular contractions 15.1
Atrial flutter 1.8
Pathologic Q waves and ST-T changes 44.6
Darlington et al. Respiratory Research 2014, 15:15 Page 3 of 6
http://respiratory-research.com/content/15/1/15patients finally diagnosed with CS are described in
Table 3. Written informed consent was obtained from all
subjects, and the study was approved by the Regional Eth-
ical Review Board in Stockholm, Sweden. All except three
patients had their human leukocyte antigen (HLA)-DRB1
analyzed.
HLA typing
HLA-class II (HLA-DR) typing was done on DNA
from blood samples with the polymerase chain reaction
(PCR) and amplification with sequence-specific primers
(SSP) [13].
Statistical analysis
Data were analyzed by Chi-square test or in the case of
small numbers by Fisher’s Exact Test. Relative risk (RR)
was calculated from the cross product ratio of the en-
tries in Table 1 and for Table 3 with patients without
CS. Statistical analyses and graphs were performed with
Graph Pad Prism 6 (GraphPad Software Inc., San Diego,
CA, USA). P-value <0.05 was regarded as significant ex-
cept from the comparison of different allele frequencies,
where p < 0.003 (p < 0.05/13) was regarded as significant
[after Bonferroni correction for the number of alleles
(n = 13)]. Sensitivity, specificity, positive and negative
predictive values of ECG-screening were calculated
considering a patient with a pathologic ECG diagnosed
with CS as true positive and false positive if the ECG
was pathologic but CS was not diagnosed during the
follow up.
Results
Out of the 1017 included patients there were 166 (16.3%)
patients with an abnormal ECG. Among these patients
there were more males (RR) (1.4) (p < 0.05), more patients
with parenchymal lung infiltrates on chest radiography




Age, years^ 44 (26–62)






^Age, years at time for sarcoidosis diagnosis: values are
medians (min – max). #Age, years at time for diagnosis of CS:
values are medians (min – max). *p < 0.05 compared to the ratio of LS/non-LS
patients without CS.(p < 0.01) and more patient deaths (2.3) (p < 0.05) com-
pared to patients with a normal ECG (Table 1).
There was a more detailed cardiac investigation per-
formed in the majority of the 166 patients with a patho-
logic ECG (69.9%, n = 116) as well as in 21.2% (n = 180)
of the 851 patients with a normal ECG, but with cardiac
related symptoms such as palpitations, pre-syncope and
syncope. Also patients with dyspnea, chest pain and
examination findings such as heart murmur were in-
cluded in this group. Included among the 166 patients
with an abnormal ECG, there were three patients with
CS that developed a pathologic ECG and symptoms in-
dicative of CS during the follow-up, but who initially
had a normal ECG and were asymptomatic in regard to
cardiac syptoms. In the group of patients with a patho-
logical ECG, 22 patients were diagnosed with CS during
the follow up. One patient diagnosed with CS had a nor-
mal ECG but a pathologic 24-hour ambulatory ECG. In
addition, 15 patients among those with a pathologic
ECG and six with initially a normal ECG were diagnosed
with cardiac disease, however judged not to be related to
sarcoidosis. These were patients with ischemic heart
disease (n = 6), valvular heart disease (n = 4) and aortic
aneurysm (n = 1). There were also nine patients with
atrial fibrillation and one patient with pacemaker that
had not received the diagnosis of CS (Table 4).
Five of the 23 patients diagnosed with CS had a normal
TTE. An additional CMR could not be performed in four
of these patients as they urgently received a pacemaker
because of severe conduction disturbances. The fifth ex-
hibited pathologic ECG changes that disappeared after
treatment with steroids. All of them had an established
sarcoidosis diagnosis; two of them had classical Löfgrens
syndrome and the other three had a positive biopsy that
confirmed the diagnosis. They were, however, incom-
pletely investigated in terms of all the criteria set forth in
the guidelines but were diagnosed with CS based on the
combination of CS criteria present and their clinicalTable 4 Clinical characteristics of patients diagnosed with
other cardiac disease than CS
Subjects 21
Gender M/F 14/7
Age, years^ 44 (29–78)






^Age, years at time for sarcoidosis diagnosis: values are
medians (min – max). #Age, years at time for diagnosis of cardiac disease:
values are medians (min – max).
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abnormal ECG were found to have CS, compared to one
(0.1%) of the 851 patients with a normal ECG (p < 0.0001).
According to the results including all 1017 patients, the
sensitivity of a pathologic ECG to predict CS was 95.6%
and the specificity was 85.5%. The positive predictive value
of a pathologic ECG was 13.3% and the negative predictive
value of a normal ECG was 99.9%.
The greatest risk for CS was observed in patients pre-
senting with a pathologic ECG combined with cardiac
related symptoms such as palpitations, pre-syncope and
syncope where 11 out of 40 (27.5%) had CS. In these
patients the risk was significantly higher compared to
patients with an abnormal ECG but without cardiac
related symptoms (11/126) (8.7%) (p < 0.01) (Figure 1).
Only one of the patients with CS who had severe heart
failure died during the median time of follow-up of
7 years (min – max, 1–38 years) at an age of 77 in what
was regarded as a sarcoidosis related death. A second
patient with severe heart failure had a successful cardiac
transplantation. Two patients received an implantableFigure 1 Frequency of CS in patients divided into four groups:
patients with no symptoms and a normal ECG (n = zero out of
800), patients with symptoms but a normal ECG (n = one out of
51), patients with no symptoms but a pathologic ECG (n = 11
out of 126) and patients with symptoms and a pathologic ECG
(n = 11 out of 40). Symptoms are palpitations, pre-syncope and
syncope. **p < 0.01, ***p < 0.001 and ****p < 0.0001.cardioverter-defibrillator (ICD) because of ventricular
tachycardias and eight patients needed a pacemaker.
The only patient with a normal ECG and CS had symp-
toms with palpitations and a pathologic 24-hour ambu-
latory ECG.
The average age in patients ultimately diagnosed with
CS was 44 years, four years after the diagnosis of sarcoid-
osis was first established. There was a tendency within the
group of CS of more males than females (RR) (1.4), and
also a higher frequency (1.3) of patients with parenchymal
lung infiltrates (stage II-IV) (statistically non-significant)
(Table 3). LS was significantly less common in patients
with CS compared to patients without the syndrome (0.2)
(p < 0.05). Smoking as evaluated by comparing never and
ever-smokers did not seem to significantly influence the
risk for CS.
Discussion
This study on an unusually large and homogenous sar-
coidosis population demonstrate the importance of an
abnormal ECG and cardiac related symptoms at disease
onset as powerful predictors of a later diagnosis of cardiac
sarcoidosis. This knowledge is of importance and may be
used in a clinical algorithm, in identifying patients that
should be followed and investigated extensively for the
presence of CS.
As described, we found a significantly increased risk
for CS in sarcoidosis patients presenting with a patho-
logic ECG in particular if they simultaneously had symp-
toms that could be cardiac related such as palpitations,
pre-syncope or syncope. Conversely, a patient with a
normal ECG and without any of the above mentioned
cardiac related symptoms had a very low risk of develop-
ing CS. Interestingly, we did however not observe any
sudden cardiac deaths during the follow-up of these pa-
tients and only one death due to severe heart failure. It
has been debated whether the diagnosis of CS per se is an
indication for ICD implantation to prevent arrhythmic
sudden cardiac death [14]. Our observations from this
study in Scandinavian Caucasians patients, suggest that
diagnosis of CS does not necessarily constitute and inde-
pendent indication for an ICD implantation, but should
probably be evaluated on a patient-by-patients basis.
Based on our experiences in patients with sarcoidosis
we also noted that, absence of or “non-significant” ECG
changes at the initial screening may later progress and
repeated examinations with ECG may therefore be re-
quired [5]. As our results show, there were phenotypic fac-
tors associated with a pathological ECG as well as with
CS. There was a tendency for a male dominance among
patients diagnosed with CS, which differs slightly from
what was reported by Iwai et al. in a previous study of aut-
opsy material from deceased sarcoidosis patients [8]. In
Caucasians, they observed an almost equal number of
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ever, they reported that cardiac involvement was more
common in females. Our investigation does not offer any
explanation(s) as to why we observe more males than fe-
males diagnosed with CS, but it must be remembered that
our cohort is diagnosed clinically and alive as opposed to
autopsy diagnosis, and direct comparisons between live
and deceased patient cohort should be done with caution.
In our cohort there was a predominance of males among
all patients with sarcoidosis leading to an inherent gender
bias to the cohort. Therefore, from the results of our in-
vestigation, it is not possible to firmly establish or refute
that gender might influence the risk of CS differently in
different ethnic groups or that gender may have different
impact on morbidity and mortality. Furthermore, never-
smokers out-numbered smokers in both patients with and
without CS. An increased risk for a pathological ECG, and
a similar tendency of an increased risk for CS, was seen in
patients with parenchymal lung infiltrates on chest radiog-
raphy. Patients with LS had a significantly reduced risk for
CS compared to non-LS patients. In line with that LS pa-
tients have a very favorable prognosis [15].
This is a retrospective cohort study, and although it is
a large cohort, the retrospective nature and other inher-
ent sources of bias may present a limitation to the inter-
pretation. First, the frequency of CS in the whole study
population may have been higher than the one we ob-
served if more or all patients with or without a patho-
logical ECG had been investigated in a more extensive
way than was possible in this historic cohort. However,
we do not believe that the essential observation of a nor-
mal ECG at baseline as a high negative predictor of CS
would be challenged. Secondly, our observations are
based on the clinical decision making and diagnosis and
not on adjudication committee diagnosis, contributing
to to less standardization. In this investigation patients
were followed from their onset of illness (few months
prior to first visit at our clinic) with an active disease
and followed as long as they exhibited signs of disease
activity. Thus all patients diagnosed with CS had an ac-
tive disease. Because of the clinical decision making vari-
ations in cardiac investigations over time, we had to
include patients diagnosed with CS (clinical decision of a
very high risk of CS) exhibiting a normal TTE and who
had not been investigated with MRI. We believe that
these patients should be included in the CS group based
on the clinical phenotype and a previous report by Metha
et al. demonstrating a pathologic TTE in only 25% of the
patients finally diagnosed with CS [16]. Similarly, one of
the patients in our material diagnosed with CS had a nor-
mal resting ECG but a pathologic twenty-four-hour ambu-
latory ECG. Suzuki et al. reported that a high frequency of
VES was more common in patients with CS than in those
without [17], and we believe that this patient should beclinically diagnosed with CS. However, we do emphasize
that these above mentioned patients are only a minor part
of the total number of patients included. Therefore, it is
expected that minor errors may be introduced in the
incidence-estimates but the basic conclusions from this
observational study is not expected to be over-ruled.
In conclusion, our results show that the risk for CS is
significantly higher in sarcoidosis patients presenting with
a pathologic ECG and in particular if they simultaneously
exhibit cardiac related symptoms such as palpitations,
pre-syncope and syncope. In accordance with our findings
we recommend that all sarcoidosis patients who have a
pathologic ECG should be further investigated for CS. Pa-
tients who have a normal ECG at first presentation and
lack the above symptoms of suspected cardiac involve-
ment appear to be at a low risk for CS. Follow-up with re-
peated ECGs at regular intervals appears to be motivated
particularly in patients with non-LS disease and should
enhance the possibility to detect CS at an early stage, and
thereby to intervene and prevent severe cardiac related
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